Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the consistency of immune responses to three different batches of an investigational chickenpox vaccine called VNS vaccine in healthy children aged 12 to 15 months who have not had chickenpox or received a chickenpox vaccine before. The study also compares the safety and immune response of the VNS vaccine to an approved chickenpox vaccine known as Varivax. This Phase 3a study is sponsored by GlaxoSmithKline and aims to better understand the immune protection provided by these vaccines. Participants are randomly assigned to receive one dose of either one of the three investigational VNS vaccine lots or one of two lots of the marketed Varivax vaccine. Along with the chickenpox vaccine, they also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine HAV, and a pneumococcal conjugate vaccine PCV which could be PCV 13, Vaxneuvance, or PCV 20 depending on availability and country recommendations. All vaccines are given on Day 1 of the study. During the study, researchers monitor the participants immune responses by measuring antibodies against varicella zoster virus VZV and other vaccine components at Day 43. They also track safety by recording any side effects or adverse events from Day 1 to Day 181. The study includes diary reports by parents and regular clinical evaluations to assess immune response and safety outcomes. Participation involves a single vaccination visit and follow-up assessments over approximately six months.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.
Actively Recruiting
Researchers are evaluating AVM0703, an immunomodulatory drug given as a single intravenous infusion, in patients aged 12 to 95 years with various lymphoid malignancies, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. This open-label Phase 12 study aims to understand its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with relapsed or refractory disease who have undergone or are ineligible for prior therapies. The study is sponsored by AVM Biotechnology Inc.